SINGAPORE, Nov. 28, 2018 /PRNewswire/ — ST Pharm Co Ltd was recognized with the Global API Manufacturing (Oligonucleotide) Growth Excellence Leadership award at the annual Frost & Sullivan Asia-Pacific Best Practices Awards banquet held at Shangri-La Singapore on 27 November.
Sanjeev Kumar, Industry Manager, Transformational Health, Asia-Pacific, Frost & Sullivan noted that ST Pharm Co Ltd’s capacity building and client networking efforts have contributed significantly to its impressive financial performance in recent years. Backed by product diversification and an increase in production, the company has laid a strong foundation for robust growth in the coming years.
"With a keen focus on innovation in product development and sustainable growth, ST Pharm is establishing itself as a major player in the small molecule and oligonucleotide API manufacturing industry. Product pricing and consistent demand for novel drugs and drug intermediates are major industry challenges which ST Pharm is addressing through its innovative R&D approach and expertise in process development, scale-up and optimization," he added.
"We are proud to be honored with the 2018 Frost & Sullivan Global API Manufacturing (Oligonucleotide) Growth Excellence Leadership award," said Dr. Kyungjin Peter Kim, President and CEO of ST Pharm.
The recipients of the annual Frost & Sullivan Asia-Pacific Best Practice Awards were identified based on in-depth research conducted by Frost & Sullivan’s analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends. The short-listed companies were evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
About ST Pharma
ST Pharm Co Ltd. (KOSDAQ: 237690), a South Korea based pharmaceutical company, is the leading player in manufacturing of Oligonucleotide and recently opened a new plant in Banwol site increasing its capacity to 1.8 mol scale.
Since 1983, ST Pharm has accumulated its technology and know-how especially in the synthesis of nucleoside based materials. Also, the company develops several new drug projects under virtual R&D strategy. By receiving this honorable award, ST Pharm will solidify its position as a forerunner in oligonucleotide API CDMOs.
Corporate Communications – Asia-Pacific
Frost & Sullivan
Related Links :